Cart
sales@molnova.com
ZEN-2759
CAS No. 1616400-50-0
ZEN-2759( —— )
Catalog No. M36339 CAS No. 1616400-50-0
ZEN-2759 is a potent BET small molecule inhibitor of BRD4 (BD1), BRD4 (BD2), and BRD4 (BD1BD2).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 86 | In Stock |
|
| 10MG | 131 | In Stock |
|
| 25MG | 220 | In Stock |
|
| 50MG | 323 | In Stock |
|
| 100MG | 451 | In Stock |
|
| 200MG | 639 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameZEN-2759
-
NoteResearch use only, not for human use.
-
Brief DescriptionZEN-2759 is a potent BET small molecule inhibitor of BRD4 (BD1), BRD4 (BD2), and BRD4 (BD1BD2).
-
DescriptionZEN-2759 is a potent BET (Bromodomain and Extra-Terminal Domain) inhibitor, with IC50 values of 0.23, 0.08 and 0.28 μM for BRD4(BD1), BRD4(BD2), and BRD4(BD1BD2), respectively.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayChromatin/Epigenetic
-
TargetEpigenetic Reader Domain
-
RecptorEpigenetic Reader Domain
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1616400-50-0
-
Formula Weight280.32
-
Molecular FormulaC17H16N2O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (356.74 mM; Ultrasonic )
-
SMILESCC=1C(C2=CN(CC3=CC=CC=C3)C(=O)C=C2)=C(C)ON1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Kharenko OA, et al. Design and Characterization of Novel Covalent Bromodomain and Extra-Terminal Domain (BET) Inhibitors Targeting a Methionine. J Med Chem. 2018 Sep 27;61(18):8202-8211. ?
molnova catalog
related products
-
SMARCA-BD ligand 1 f...
SMARCA-BD ligand 1 for Protac is a compound that binds to SMARCA2, the BAF ATPase subunit, utilizing Protac technology to degrade SMARCA2.
-
MS436
MS436 is a diazobenzene-based small-molecule inhibitor for the BRD4 bromodomains with a Ki value of 30-50 nM.
-
PBRM1-BD2-IN-8
PBRM1-BD2-IN-8 (compound 34) is a potent PBRM1 Bromodomain inhibitor with PBRM1-BD2 Kd of 4.4 μM, PBRM1-BD2 IC50 of 0.16 μM, and PBRM1-BD5 Kd of 25 μM; PBRM1-BD2-IN-8 shows anti-cancer activity.
